SCHEMBL11028623

SCHEMBL11028623

Nc1nc2ccccn2c1-c1ccncc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 9/20 0.69
CDK4 P11802 1/20 0.44
CDK2 P24941 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GLA P06280 2/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
HSD17B10 Q99714 1/20 0.44
DAPK3 O43293 1/20 0.43
JAK2 O60674 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
ABL1 P00519 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
MET P08581 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19048703 0.88 USP7 (0.76) USP7CDK4CDK2KDM4EALDH1A1
SCHEMBL11026812 0.83 USP7 (0.60) USP7CDK4CDK2KDM4EALDH1A1
SCHEMBL11031736 0.82 USP7 (0.63) USP7CDK4CDK2KDM4EALDH1A1
SCHEMBL947308 0.80 CDK2 (0.55) USP7CDK4CDK2KDM4EALDH1A1
SCHEMBL752682 0.77 USP7 (0.50) USP7CDK2KDM4EALDH1A1GAA
SCHEMBL3084111 0.76 HSP90AA1 (0.44) USP7KDM4EALDH1A1GLAGAA
SCHEMBL5765187 0.76 USP7 (0.46) USP7CDK4CDK2KDM4EALDH1A1
SCHEMBL3081742 0.76 USP7 (0.46) USP7KDM4EALDH1A1GLAGAA
SCHEMBL9292753 0.74 AKT1 (0.50) USP7KDM4EALDH1A1NPC1PRKD3
SCHEMBL9298472 0.74 CSNK1D (0.58) KDM4EALDH1A1HPGDPRKD3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES INC 2025-03-27 US disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS DYRK2, DYRK1A, DYRK1B USP7 3623/4885CDK4 1402/4885CDK2 549/4885
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD USP7 3522/4885CDK4 207/4885CDK2 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.